WHO. Global hepatitis report 2017.: World Health Organization; 2017.

Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973–82 (2014-05-22).

Article  PubMed  Google Scholar 

WHO. Combating hepatitis B and C to reach elimination by 2030. Advocacy brief. Geneva: World Health Organization; 2016. https://www.who.int/publications/i/item/combating-hepatitis-b-and-c-to-reach-elimination-by-2030. Accessed 13 Jun 2022.

Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline for the prevention and treatment of hepatitis C (2022 version). Zhonghua Gan Zang Bing Za Zhi. 2022;30(12):1332–48.

Hui Z, Lai W, Guiqiang W. Healthy China 2030 white paper on action against the threat of Hepatitis C. http://www.cphcf.org.cn/zgcb/contents/650/30644.html. Accessed 13 Nov 2022.

Mei X, Lu H. Prevalence, diagnosis, and treatment of hepatitis C in Mainland China. Glob Health Med. 2021;3(5):270–5 (2021-10-31).

Article  PubMed  PubMed Central  Google Scholar 

Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571–83 (2011-08-13).

Article  PubMed  PubMed Central  Google Scholar 

Zhang Q, Qi W, Wang X, Zhang Y, Xu Y, Qin S, et al. Epidemiology of Hepatitis B and Hepatitis C infections and benefits of programs for hepatitis prevention in northeastern China: a cross-sectional study. Clin Infect Dis. 2016;62(3):305–12 (2016-02-01).

Article  PubMed  Google Scholar 

Rao HY, Duan ZP, Wang GQ, Wei L. Highlights of the guidelines of prevention and treatment for hepatitis C (2019 version). Zhonghua Gan Zang Bing Za Zhi. 2020;28(2):129–32 (2020-02-20).

CAS  PubMed  Google Scholar 

National Healthcare Security Administration. Notice on the inclusion of the 2019 negotiated drugs into the national basic medical insurance, work injury insurance and maternity insurance drug catalog; 2019. http://www.nhsa.gov.cn/art/2019/11/28/art_53_2057.html. Accessed 13 Nov 2022.

Lim AG, Walker JG, Mafirakureva N, Khalid GG, Qureshi H, Mahmood H, et al. Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis. Lancet Glob Health. 2020;8(3):e440–50 (2020-03-01).

Article  PubMed  PubMed Central  Google Scholar 

Chen YS, Li L, Cui FQ, Xing WG, Wang L, Jia ZY, et al. A sero-epidemiological study on hepatitis C in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2011;32(9):888–91 (2011-09-01).

PubMed  Google Scholar 

He T, Li K, Roberts MS, Spaulding AC, Ayer T, Grefenstette JJ, et al. Prevention of Hepatitis C by screening and treatment in U.S. prisons. Ann Intern Med. 2016;164(2):84–92 (2016-01-19).

Article  PubMed  Google Scholar 

National Bureau of Statistics. Basic information on the census population. https://data.stats.gov.cn/easyquery.htm?cn=C01. Accessed 13 Sept 2023.

United Nations. Department of Economic and Social AffairsPopulation Division.

Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192–207 (2017-12-01).

Article  PubMed  PubMed Central  Google Scholar 

Zhang L, Ruan YH, Jiang ZQ, Yang ZN, Liu SZ, Zhou F, et al. An 1-year prospective cohort study on mortality of injecting drug users. Zhonghua Liu Xing Bing Xue Za Zhi. 2005;26(3):190–3 (2005-03-01).

PubMed  Google Scholar 

Liu EW, Wang SJ, Liu Y, Liu W, Chen ZS, Li XY, et al. Mortality of HIV infected clients treated with methadone maintenance treatment in Yili Kazakh autonomous prefecture. Zhonghua Yu Fang Yi Xue Za Zhi. 2011;45(11):979–84 (2011-11-01).

PubMed  Google Scholar 

Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418–31 (2008-08-01).

Article  PubMed  Google Scholar 

Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463–72 (1997-02-01).

Article  CAS  PubMed  Google Scholar 

Wei X, Zhao J, Yang L. Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective. BMJ Glob Health. 2020;5(11): e003194 (2020-11-01).

Article  PubMed  PubMed Central  Google Scholar 

Chen GF, Wei L, Chen J, Duan ZP, Dou XG, Xie Q, et al. Will Sofosbuvir/Ledipasvir (Harvoni) be cost-effective and affordable for chinese patients infected with Hepatitis C virus? An economic analysis using real-world data. PLOS One. 2016;11(6): e155934 (2016-01-20).

Google Scholar 

National Bureau of Statistics.Renminbi exchange rate (annual average). https://data.stats.gov.cn/easyquery.htm?cn=C01&zb=A060J&sj=2021. Accessed 13 Nov 2022.

Department of population and employment statistics, national bureau of statistics. China population and employment statistics yearbook 2021. Beijing: China Statistics Press, 2021.

Degenhardt L, Charlson F, Stanaway J, Larney S, Alexander LT, Hickman M, et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16(12):1385–98 (2016-12-01).

Article  PubMed  Google Scholar 

Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019;4(6):435–44 (2019-06-01).

Article  PubMed  PubMed Central  Google Scholar 

The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–76 (2017-03-01).

Article  Google Scholar 

Planning, Development and Information Technology Division. 2021 China's health and health care development statistics bulletin. http://www.nhc.gov.cn/guihuaxxs/s3586s/202207/51b55216c2154332a660157abf28b09d.shtml. Accessed 13 Nov 2022.

Scott N, Win TM, Tidhar T, Htay H, Draper B, Aung P, et al. Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits. Lancet Reg Health West Pac. 2021;10: 100129 (2021-05-01).

PubMed  PubMed Central  Google Scholar 

Trickey A, Hiebert L, Perfect C, Thomas C, El KJ, Vickerman P, et al. Hepatitis C virus elimination in Indonesia: epidemiological, cost and cost-effectiveness modelling to advance advocacy and strategic planning. Liver Int. 2020;40(2):286–97 (2020-02-01).

Article  PubMed  Google Scholar 

Xia C, Xu X, Zhao X, Hu S, Qiao Y, Zhang Y, et al. Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study. BMC Med. 2021;19(1):62 (2021-03-03).

Article  PubMed  PubMed Central  Google Scholar 

Song Y, Li Y, Cheng H, Du X, Mi J, Le LV, et al. Eliminate Hepatitis C as a public health threat: a narrative review of strategies, gaps, and opportunities for China. Infect Dis Ther. 2022;11(4):1427–42 (2022-08-01).

PubMed  PubMed Central  Google Scholar 

Xia C, Hu S, Xu X, Zhao X, Qiao Y, Broutet N, et al. Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study. Lancet Public Health. 2019;4(9):e462–72 (2019-09-01).

Article  PubMed  Google Scholar 

Su S, Wong WC, Zou Z, Cheng DD, Ong JJ, Chan P, et al. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. Lancet Glob Health. 2022;10(2):e278–87 (2022-02-01).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adee M, Zhuo Y, Zhan T, Chen Q, Toumi A, Ayer T, et al. A tool to inform Hepatitis C elimination: a case for Hepatitis C elimination in China. Clin Liver Dis (Hoboken). 2021;17(3):99–106.

Article  PubMed  Google Scholar 

Wu T, Lin F, Wang J, Li H, Liu M, Zhang YR, et al. Hepatitis C elimination among drug users in China: challenges, strategies and experiences. Zhonghua Gan Zang Bing Za Zhi. 2022;30(9):1002–6 (2022-09-20).

CAS  PubMed  Google Scholar 

Pan L, Wan H, Gao Y, Wen J. Awareness of HCV prevention knowledge and its related factors among attendants in methadone maintenance treatmentclinics in Yunnan province. Chin J AIDS &STD. 2018;24(12):1217–20.

Klein MB. Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations. Lancet Gastroenterol Hepatol. 2022;7(4):277–9 (2022-04-01).

Article  PubMed  PubMed Central  Google Scholar 

Jiabin C. Research on the control mode of drug addicts under the vision of socialised anti-drugs. Res Crime Rehabil. 2021;12:51–7.

Google Scholar 

Kong FJ, Zhang L. Community-based drug rehabilitation: current situation, problems and paths. J Guangxi Police College. 2020;02(33):95–102.

Google Scholar 

Li L, Wu Z, Liang LJ, Lin C, Guan J, Jia M, et al. Reducing HIV-related stigma in health care settings: a randomized controlled trial in China. Am J Public Health. 2013;103(2):286–92 (2013-02-01).

Article  PubMed  PubMed Central  Google Scholar 

Heffernan A, Ma Y, Nayagam S, Chan P, Chen Z, Cooke GS, et al. Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China. PLOS One. 2021;16(1): e245288 (2021-01-20).

Google Scholar 

Zhao Z, Chu M, Guo Y, Yang S, Abudurusuli G, Frutos R, et al. Feasibility of Hepatitis C elimination in China: from epidemiology, natural history, and intervention perspectives. Front Microbiol. 2022;13: 884598.